The change in the kinetic energy of the particle

We may then state the above equation in this way: The work done by the resultant force acting on a particle is equal to the change in the kinetic energy of the particle.

Impact blocks
The change in the kinetic energy (Shutterstock)

A constant force, acting on a particle of mass m, will produce a constant acceleration a. Let us choose the x-axis to be in the common direction of F and a. What is the work done by this force on the particle in causing a displacement x? We have, for constant acceleration, the relations a = ( V - v ) / t and x = ½ ( V + v ) t. Here v is the particle’s speed at t = 0 and V is its speed at time t. The the work done is W = F x = m a x = m ( ( V - v ) / t ) ( ½ ( V + v ) ) t = ½ m V² - ½ m v². We call one-half the product of the mass of a body and the square of its speed the kinetic energy of the body. If we represent kinetic energy by the symbol K, then K = ½ m v². We may then state the above equation in this way: The work done by the resultant force acting on a particle is equal to the change in the kinetic energy of the particle.

A constant force, acting on a particle of mass m, will produce a constant acceleration a. Let us choose the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

 
• By 

Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By 

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Sponsored By:

Nancy Tests SPARC-931-part

The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains